Posts by AiViva BioPharma
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
Costa Mesa, Calif., May 22, 2023 – AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of…
Read MoreAiViva BioPharma Announces New Patent Received
Newport Beach, California – August 15, 2022 – AiViva Biopharma, a clinical-stage biopharmaceutical company has received patent US 11,400,089 on August 2, 2022. This patent is a method of use…
Read MoreAiViva BioPharma is recognized by Life Sciences Review as Top 20 Clinical-Stage Biopharmaceutical Company for 2022
Life Sciences Review Recognizes AiViva Top 20 Clinical-Stage Biopharmaceutical Companies of 2022Downdload PDF File > Life Sciences Review Recognizes AiViva Page 2Download PDF File >
Read MoreAiViva BioPharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer
Novel Non-surgical Intradermal Treatment NEWPORT BEACH, Calif., October 2, 2020 (GLOBE NEWSWIRE) – AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun dosing patients diagnosed with superficial…
Read MoreAiViva BioPharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
AiViva Biopharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing AIV001 was shown to be safe and well tolerated after local intradermal…
Read More